X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare JUBILANT LIFE SCIENCES with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs ALKEM LABORATORIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES ALKEM LABORATORIES JUBILANT LIFE SCIENCES/
ALKEM LABORATORIES
 
P/E (TTM) x 13.3 - - View Chart
P/BV x 1.9 5.8 32.1% View Chart
Dividend Yield % 0.6 0.7 84.0%  

Financials

 JUBILANT LIFE SCIENCES   ALKEM LABORATORIES
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-18
ALKEM LABORATORIES
Mar-16
JUBILANT LIFE SCIENCES/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,0391,589 65.4%   
Low Rs6001,232 48.7%   
Sales per share (Unadj.) Rs482.6417.5 115.6%  
Earnings per share (Unadj.) Rs40.756.3 72.3%  
Cash flow per share (Unadj.) Rs67.464.7 104.1%  
Dividends per share (Unadj.) Rs3.0012.70 23.6%  
Dividend yield (eoy) %0.40.9 40.7%  
Book value per share (Unadj.) Rs262.3292.9 89.5%  
Shares outstanding (eoy) m155.79119.57 130.3%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x1.73.4 50.3%   
Avg P/E ratio x20.125.1 80.3%  
P/CF ratio (eoy) x12.221.8 55.8%  
Price / Book Value ratio x3.14.8 64.9%  
Dividend payout %7.422.6 32.7%   
Avg Mkt Cap Rs m127,670168,653 75.7%   
No. of employees `0002.4NA-   
Total wages/salary Rs m15,5599,171 169.6%   
Avg. sales/employee Rs Th30,861.4NM-  
Avg. wages/employee Rs Th6,387.0NM-  
Avg. net profit/employee Rs Th2,604.4NM-  
INCOME DATA
Net Sales Rs m75,17849,915 150.6%  
Other income Rs m4001,645 24.3%   
Total revenues Rs m75,57951,561 146.6%   
Gross profit Rs m15,1848,482 179.0%  
Depreciation Rs m4,1511,006 412.7%   
Interest Rs m2,843671 423.9%   
Profit before tax Rs m8,5918,451 101.7%   
Minority Interest Rs m0-114 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,2471,606 139.9%   
Profit after tax Rs m6,3446,731 94.3%  
Gross profit margin %20.217.0 118.9%  
Effective tax rate %26.219.0 137.6%   
Net profit margin %8.413.5 62.6%  
BALANCE SHEET DATA
Current assets Rs m31,89827,062 117.9%   
Current liabilities Rs m20,04715,324 130.8%   
Net working cap to sales %15.823.5 67.0%  
Current ratio x1.61.8 90.1%  
Inventory Days Days6867 101.6%  
Debtors Days Days5541 133.0%  
Net fixed assets Rs m60,71512,610 481.5%   
Share capital Rs m156239 65.2%   
"Free" reserves Rs m40,71034,490 118.0%   
Net worth Rs m40,86535,027 116.7%   
Long term debt Rs m30,4781,212 2,515.5%   
Total assets Rs m96,17654,387 176.8%  
Interest coverage x4.013.6 29.6%   
Debt to equity ratio x0.70 2,156.1%  
Sales to assets ratio x0.80.9 85.2%   
Return on assets %9.613.6 70.2%  
Return on equity %15.519.2 80.8%  
Return on capital %16.024.9 64.5%  
Exports to sales %012.9 0.0%   
Imports to sales %03.1 0.0%   
Exports (fob) Rs mNA6,461 0.0%   
Imports (cif) Rs mNA1,540 0.0%   
Fx inflow Rs m14,4026,563 219.4%   
Fx outflow Rs m12,0443,012 399.9%   
Net fx Rs m2,3583,552 66.4%   
CASH FLOW
From Operations Rs m13,0327,259 179.5%  
From Investments Rs m-6,1771,864 -331.3%  
From Financial Activity Rs m-9,011-9,273 97.2%  
Net Cashflow Rs m-2,123-150 1,415.1%  

Share Holding

Indian Promoters % 45.6 66.9 68.2%  
Foreign collaborators % 3.5 0.0 -  
Indian inst/Mut Fund % 8.7 33.1 26.3%  
FIIs % 21.2 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 0.0 -  
Shareholders   23,815 68,381 34.8%  
Pledged promoter(s) holding % 15.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   MERCK  STERLING BIOTECH  ASTRAZENECA PHARMA  GSK PHARMA  PLETHICO PHARMA  

Compare JUBILANT LIFE SCIENCES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End on a Strong Note; Sensex Ends 489 Points Higher(Closing)

After opening the day marginally lower, Indian share markets witnessed most of the buying interest during closing hours and ended their trading session on a strong note.

Related Views on News

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY19); Net Profit Down 166.0% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 1 bn (down 166.0% YoY). Sales on the other hand came in at Rs 24 bn (up 5.9% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY19); Net Profit Up 25.7% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 25.7% YoY). Sales on the other hand came in at Rs 24 bn (up 15.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (2QFY19); Net Profit Up 67.2% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 67.2% YoY). Sales on the other hand came in at Rs 23 bn (up 38.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY19); Net Profit Up 39.4% (Quarterly Result Update)

Jul 31, 2018 | Updated on Jul 31, 2018

For the quarter ended June 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 39.4% YoY). Sales on the other hand came in at Rs 21 bn (up 30.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why Modi 2.0 Will Be Great for These 7 Stocks(Profit Hunter)

Jun 10, 2019

The government's focus on Infra, electricity, water for all will be the key factors for Sensex 1,00,000.

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Jun 20, 2019 03:35 PM

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES 8-QTR ANALYSIS

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS